Micafungin Sodium interactions
Checked as Micafungin in this data source.
Full monograph for Micafungin SodiumCheck it against another medicine
Medicines
6 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amphotericin B | Moderate | Others | The concomitant use of micafungin and amphotericin B may increase systemic exposure to amphotericin. The mechanism is unknown. Coadministration resulted in a… | 3 sources — open the full entry |
| Everolimus | Moderate | Absorption | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration… | 4 sources — open the full entry |
| Lurbinectedin | Moderate | Metabolism | Coadministration with a CYP450 3A4 inhibitor may increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions… | 3 sources — open the full entry |
| Ribociclib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and risk of adverse effects of ribociclib, which is a substrate of the… | 5 sources — open the full entry |
| Itraconazole | Minor | Metabolism | Coadministration with micafungin may increase the plasma concentrations of itraconazole. The exact mechanism of interaction is unknown but may involve… | 12 sources — open the full entry |
| Nifedipine | Minor | Metabolism | Coadministration with micafungin may increase the plasma concentrations of nifedipine. The exact mechanism of interaction is unknown but may involve inhibition… | 20 sources — open the full entry |
Conditions
Conditions in which Micafungin Sodium needs care, as documented in this source.
Anemia
ModerateAcute, transient, and asymptomatic intravascular hemolysis and hemoglobinuria were reported in a healthy volunteer given an infusion of micafungin 200 mg and oral prednisolone 20 mg. Isolated cases of significant hemolysis and hemolytic anemia have also been reported in patients treated with micafungin. Therapy with micafungin should be administered cautiously in patients with preexisting anemia.
1 source
- "Product Information. Mycamine (micafungin)." Fujisawa (2005):
Kidney Diseases
ModerateElevations in BUN and creatinine, as well as isolated cases of significant renal dysfunction or acute renal failure, have been reported in patients treated with micafungin. In controlled clinical trials, the incidence of drug-related renal adverse events was 0.4% for patients receiving micafungin and 0.5% for patients receiving fluconazole. Therapy with micafungin should be administered cautiously in patients with preexisting renal impairment. Renal function should be monitored regularly during therapy.
1 source
- "Product Information. Mycamine (micafungin)." Fujisawa (2005):
Liver Diseases
ModerateLaboratory abnormalities in liver function tests have been observed in healthy volunteers and patients treated with echinocandins, and clinical hepatic abnormalities have occurred in some patients with serious underlying conditions who were receiving multiple concomitant medications with echinocandin therapy. Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have also been reported, although a causal relationship has not been established. Therapy with echinocandins should be administered cautiously in patients with preexisting liver disease. Liver function should be monitored regularly during therapy.
3 sources
- "Product Information. Cancidas (caspofungin)." Merck & Co., Inc (2001):
- "Product Information. Mycamine (micafungin)." Fujisawa (2005):
- "Product Information. Eraxis (anidulafungin)." Pfizer U.S. Pharmaceuticals Group (2006):